BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 18, 2012
 |  BioCentury  |  Emerging Company Profile

Armour: Relaxin in CRPC

Armour targets relaxin in prostate cancer; may complement anti-androgen drugs

Armour Therapeutics Inc.'s relaxin receptor antagonists may provide a complementary hormonal therapy that can be given either with or after anti-androgen therapy in prostate cancer patients. Targeting a secondary pathway alongside an androgen pathway could delay the time to when the disease becomes hormone refractory.

Prostate cancer therapies have predominantly targeted the androgen pathway, as aberrant androgen production drives tumor growth and metastases. These treatments include older therapies such as androgen hormone antagonists and newer compounds such as Zytiga abiraterone from Johnson & Johnson, which suppresses androgen synthesis, and Medivation Inc.'s enzalutamide, a next-generation androgen receptor antagonist.

Relaxin is a reproductive peptide hormone that in males is produced predominantly in the prostate; however, its function is not well understood. In females, the hormone is produced predominantly in the ovary and is believed to be involved in childbirth, according to CEO Josh Silvertown.

Multiple companies, including Novartis AG and Ambrx Inc., are developing recombinant relaxin hormones that function as relaxin receptor agonists to treat heart failure. The...

Read the full 845 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >